CERTIFICATE OF ANALYSIS

PuriLab Analytical

Retatrutide 20 mg

RT-2026-155 Lot RT20-2611001-1 Analyzed November 20, 2026



TIMELINE

ORDERED
November 18, 2026

RECEIVED
November 20, 2026

ANALYZED
November 20, 2026

SAMPLE

NAME
Retatrutide 20 mg

EXPECTED
Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
P-LabTest

TEST TYPE
Content & purity, fentanyl

METHOD
HPLC-UV

GROUP TEST

VIALS TESTED
1 vial, shared result

CONTRIBUTORS
7 people

SHARED BY
Joe Glez, Raul Flores, Carlos Delgado, Laura Reveles, Joe Glez 2 (Saudi Vel Spot), Raul Flores (yari), Joe Glez 3

CONTENT, HOW MUCH IS IN IT

19.00 mg

Label claim: 20 mg

PURITY, HOW CLEAN IT IS

99.5%

Measured, not estimated. Purity is calculated from the full chromatogram shown above.


FENTANYL

NOT DETECTED

Screening cutoff 20 ng/mL

CHROMATOGRAM

HPLC-UV



- 13.40 min, Retatrutide, 99.5%

ANALYST COMMENTS

White lyophilized powder, blue flip-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 20, 2026

VERIFICATION CODE

RT-7TA7-VIFO

Verify at purilab.org/verify/RT-7TA7-VIFO

SCAN TO VERIFY

RT-7TA7-VIFO

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.